It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Story Feb. 13 - Moderna: The big biotech is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees. The IT workforce reductions come as ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore more details here.

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025 ...

And the biotech says it's on track to deliver as many as 10 product approvals by 2027. If Moderna even makes it part of the way to that goal, it could be transformational for the company's ...

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA ...

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

The R.I. Life Science Hub is leading development of our state’s first life science incubator, and is already generating a great return on our investment, writes House Speaker K. Joseph Shekarchi ...